Cardiff Oncology, Inc.
CRDF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.12 | -0.36 | -0.07 | 0.26 |
| FCF Yield | -18.27% | -47.59% | -56.87% | -9.91% |
| EV / EBITDA | -3.25 | -1.04 | -1.20 | -7.95 |
| Quality | ||||
| ROIC | -57.56% | -63.17% | -35.24% | -19.64% |
| Gross Margin | 100.00% | 100.00% | 48.19% | -39.28% |
| Cash Conversion Ratio | 0.83 | 0.75 | 0.87 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.95% | 10.78% | 1.79% | 13.64% |
| Free Cash Flow Growth | -20.03% | 9.34% | -49.33% | -40.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.04 | 0.43 | 0.34 | 0.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,942.51 | -1,587.58 | -2,840.65 | -506.53 |